Evolving guidelines for intravitreous injections.

@article{Aiello2004EvolvingGF,
  title={Evolving guidelines for intravitreous injections.},
  author={Lloyd Paul Aiello and Alexander J. Brucker and Stanley Chang and Emmett T. Cunningham and Donald J. D'amico and Harry W. Flynn and Lisa R. Grillone and Steve Hutcherson and Jeffrey M. Liebmann and Terrence P O'brien and Ingrid U. Scott and Richard F. Spaide and Christopher N. Ta and Michael T. Trese},
  journal={Retina},
  year={2004},
  volume={24 5 Suppl},
  pages={S3-19}
}
Intravitreous (i.v.t.) injection is increasingly being incorporated into the management of ocular diseases. While only fomivirsen sodium (Vitravene) is currently approved by the Food and Drug Administration as an i.v.t. injection, the number of approved i.v.t. injections indications is anticipated to grow on the basis of promising results from ongoing clinical studies. Despite the potential benefits that may be derived from intraocular injections of different agents, no guidelines have been… CONTINUE READING